Acumen Pharmaceuticals, Inc. Accrued Liabilities, Current
Acumen Pharmaceuticals, Inc. (ABOS) had Accrued Liabilities, Current of $7.53 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-12
- 2026-06-30: Accrued Liabilities, Current $7.53M.
- 2026-03-31: Accrued Liabilities, Current $5.27M.
- 2025-12-31: Accrued Liabilities, Current $10.07M.
- 2025-09-30: Accrued Liabilities, Current $7.79M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $7.53M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $5.27M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $10.07M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | $7.79M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $11.65M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $6.71M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $6.62M 10-K · filed 2026-03-26 | |
| 2024-09-30 | $4.93M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $4.00M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $2.90M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $6.45M 10-K · filed 2025-03-27 | $6.34M 10-K · filed 2024-03-26 |
| 2023-09-30 | $3.17M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $2.37M 10-Q · filed 2023-08-08 | |
| 2022-12-31 | $3.35M 10-K · filed 2024-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |